Bristol-Myers Squibb Company

NYSE: BMY
$56.12
-$2.39 (-4.1%)
Real Time Data Delayed 15 Min.

BMY Articles

The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
The top analyst upgrades, downgrades and other research calls from Wednesday include Chevron, Chipotle Mexican Grill, Exxon Mobil, Goldman Sachs, GoPro, IBM, Merck, Petrobras, UnitedHealth, Visa and...
The top analyst upgrades, downgrades and other research calls from Monday include Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66 and United Rentals.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.